Selective Substituted Pyridine DNMT1 Inhibitors for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNMT inhibitors used in treating cancer and hemoglobin disorders like sickle cell anemia and beta-thalassemia face issues with toxicity, unsuitable dosing routes, and limited efficacy in solid tumors and oral bioavailability, necessitating a novel compound that selectively targets DNMT1 to correct aberrant methylation patterns.
Innovation Solution
Development of novel substituted pyridine derivatives that act as selective inhibitors of DNMT1, capable of administering them as pharmaceutical compositions to treat diseases associated with inappropriate DNMT1 activity, including cancer and beta hemoglobinopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current DNMT inhibitors are used to treat cancer and hemoglobin disorders, then therapeutic effect is achieved, but toxicity increases and oral bioavailability is limited
Solution Approach 1:
The patent applies local quality by designing a compound with selective affinity for DNMT1 versus other DNMT family members. The substituted pyridine structure with specific substituents (R1, R2, R3, R4, R5, R6) creates localized interaction features that preferentially bind to DNMT1's catalytic domain, achieving therapeutic effect while reducing off-target toxicity to other enzymes
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure parameters of DNMT inhibitors. By varying substituents at different positions on the pyridine ring (different R groups), the invention optimizes parameters such as molecular weight, lipophilicity, and electrostatic properties to improve oral bioavailability and reduce toxicity while maintaining DNMT1 inhibition efficacy
2Reliability
If current DNMT inhibitors are administered, then cancer treatment is achieved, but dosing route limitations and poor oral bioavailability occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying physicochemical properties of the inhibitor molecules. By adjusting substituents to optimize molecular weight (150-500 Da), logP values (1-5), and hydrogen bond donors/acceptors, the compounds achieve improved oral absorption and bioavailability while maintaining cancer treatment efficacy
Solution Approach 2:
The patent uses local quality by introducing specific functional groups at strategic positions on the pyridine ring to enhance oral bioavailability. For example, adding polar substituents improves solubility for absorption, while hydrophobic substituents enhance membrane permeability, creating localized properties that collectively improve oral delivery
3Reliability
If DNMT1 is inhibited to reverse aberrant methylation patterns, then cancer treatment is improved, but selectivity against other DNMT family members must be maintained
Solution Approach 1:
The patent applies local quality by designing substituents that create specific local interactions with residues unique to DNMT1's active site. The substituted pyridine structure with specific R groups at defined positions forms localized hydrogen bonds, pi-stacking, or hydrophobic interactions that are geometry-dependent and selective for DNMT1 over DNMT3A and DNMT3B
Solution Approach 2:
The patent employs asymmetry by creating chiral centers or asymmetric substitution patterns on the pyridine ring that match the asymmetric geometry of DNMT1's binding pocket. This asymmetric design ensures selective fitting into DNMT1's active site while preventing binding to other DNMT family members with different spatial arrangements
Data Source
AI summary
The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.